[1] |
Chen R, Hou XM, Yang LP, et al. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors:a systematic review and meta-analysis[J]. Thorac Cancer, 2019, 10(4): 607-623.
|
[2] |
Iravani A, Osman MM, Weppler AM, et al. FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment[J]. Eur J Nucl Med Mol Imaging, 2020, 47(12): 2776-2786.
|
[3] |
Rizzo A, Mollica V, Massari F. Expression of programmed cell death ligand 1 as a predictive biomarker in metastatic urothelial carcinoma patients treated with first-line immune checkpoint inhibitors versus chemotherapy: a systematic review and meta-analysis[J]. Eur Urol Focus, 2022, 8(1): 152-159.
|
[4] |
Yoneda K, Imanishi N, Ichiki Y, et al. Immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC)[J]. J UOEH, 2018, 40(2): 173-189.
|
[5] |
He YD, Xu WD, Xiao YT, et al. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials[J]. Signal Transduct Target Ther, 2022, 7(1): 198.
|
[6] |
Kim TK, Vandsemb EN, Herbst RS, et al. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities[J]. Nat Rev Drug Discov, 2022, 21(7): 529-540.
|
[7] |
Yi M, Zheng XL, Niu MK, et al. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions[J]. Mol Cancer, 2022, 21(1): 28.
|
[8] |
Maruhashi T, Sugiura D, Okazaki IM, et al. Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity[J]. Immunity, 2022, 55(5): 912-924.e8.
|
[9] |
Goldberg MV, Drake CG. LAG-3 in cancer immunotherapy[J]. Curr Top Microbiol Immunol, 2011, 344: 269-278.
|
[10] |
Sordo-Bahamonde C, Lorenzo-Herrero S, González-Rodríguez AP, et al. LAG-3 blockade with relatlimab (BMS-986016) restores anti-leukemic responses in chronic lymphocytic leukemia[J]. Cancers, 2021, 13(9): 2112.
|
[11] |
Wen SQ, Lu HZ, Wang DK, et al. TCF-1 maintains CD8+ T cell stemness in tumor microenvironment[J]. J Leukoc Biol, 2021, 110(3): 585-590.
|
[12] |
Acharya N, Sabatos-Peyton C, Anderson AC. Tim-3 finds its place in the cancer immunotherapy landscape[J]. J Immunother Cancer, 2020, 8(1): e000911.
|
[13] |
Ganjalikhani Hakemi M, Jafarinia M, Azizi M, et al. The role of TIM-3 in hepatocellular carcinoma: a promising target for immunotherapy[J]? Front Oncol, 2020, 10: 601661.
|
[14] |
De Mingo Pulido á, Gardner A, Hiebler S, et al. TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer[J]. Cancer Cell, 2018, 33(1): 60-74.e6.
|
[15] |
Banerjee S, Oaknin A, Sanchez-Simon I, et al. 518 Phase 1B trial of monalizumab (NKG2A inhibitor) plus durvalumab: safety and efficacy in patients with metastatic ovarian, cervical, and microsatellite-stable endometrial cancers[J]. Int J Gynecol Cancer, 2020, 30: A86-A87.
|
[16] |
Tinker AV, Hirte HW, Provencher D, et al. Dose-ranging and cohort-expansion study of monalizumab (IPH2201) in patients with advanced gynecologic malignancies: a trial of the Canadian cancer trials group (CCTG): IND221[J]. Clin Cancer Res, 2019, 25(20): 6052-6060.
|
[17] |
Yang S, Wei W, Zhao Q. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy[J]. Int J Biol Sci, 2020, 16(11): 1767-1773.
|
[18] |
Podojil JR, Glaser AP, Baker D, et al. Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma[J]. OncoImmunology, 2020, 9(1): 1744897.
|
[19] |
Willingham SB, Hotson AN, Miller RA. Targeting the A2AR in cancer; early lessons from the clinic[J]. Curr Opin Pharmacol, 2020, 53: 126-133.
|
[20] |
Ghalamfarsa G, Kazemi MH, Raoofi Mohseni S, et al. CD73 as a potential opportunity for cancer immunotherapy[J]. Exp Opin Ther Targets, 2019, 23(2): 127-142.
|
[21] |
Murter B, Pan XY, Ophir E, et al. Mouse PVRIG has CD8+ T cell-specific coinhibitory functions and dampens antitumor immunity[J]. Cancer Immunol Res, 2019, 7(2): 244-256.
|
[22] |
Garon EB, Rizvi NA, Hui RN, et al. Pembrolizumab for the treatment of non-small-cell lung cancer[J]. N Engl J Med, 2015, 372(21): 2018-2028.
|
[23] |
Daud AI, Wolchok JD, Robert C, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma[J]. J Clin Oncol, 2016, 34(34): 4102-4109.
|
[24] |
Bai RL, Chen NF, Li LY, et al. Mechanisms of cancer resistance to immunotherapy[J]. Front Oncol, 2020, 10: 1290.
|
[25] |
Ngeow J, Eng C. PTEN in hereditary and sporadic cancer[J]. Cold Spring Harb Perspect Med, 2020, 10(4): a036087.
|
[26] |
Zhuang Y, Liu C, Liu JQ, et al. Resistance mechanism of PD-1/PD-L1 blockade in the cancer-immunity cycle[J]. Oncol Targets Ther, 2020, 13: 83-94.
|
[27] |
Chen KQ, Wang JM, Yuan RX, et al. Tissue-resident dendritic cells and diseases involving dendritic cell malfunction[J]. Int Immunopharmacol, 2016, 34: 1-15.
|
[28] |
Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion[J]. Nat Rev Cancer, 2021, 21(5): 298-312.
|
[29] |
Dahmani A, Delisle JS. TGF-β in T cell biology: implications for cancer immunotherapy[J]. Cancers, 2018, 10(6): 194.
|
[30] |
Moesta AK, Li XY, Smyth MJ. Targeting CD39 in cancer[J]. Nat Rev Immunol, 2020, 20(12): 739-755.
|
[31] |
Shi LS, Yang L, Wu ZY, et al. Adenosine signaling: next checkpoint for gastric cancer immunotherapy[J]? Int Immunopharmacol, 2018, 63: 58-65.
|
[32] |
Ye Q, Wang CL, Xian J, et al. Expression of programmed cell death protein 1 (PD-1) and indoleamine 2, 3-dioxygenase (IDO) in the tumor microenvironment and in tumor-draining lymph nodes of breast cancer[J]. Hum Pathol, 2018, 75: 81-90.
|
[33] |
Haist M, Stege H, Grabbe S, et al. The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment[J]. Cancers, 2021, 13(2): 210.
|
[34] |
Zhang J, Endres S, Kobold S. Enhancing tumor T cell infiltration to enable cancer immunotherapy[J]. Immunotherapy, 2019, 11(3): 201-213.
|
[35] |
Dai Phung C, Nguyen HT, Choi JY, et al. Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic cell death[J]. J Control Release, 2019, 315: 126-138.
|
[36] |
Showalter A, Limaye A, Oyer JL, et al. Cytokines in immunogenic cell death: applications for cancer immunotherapy[J]. Cytokine, 2017, 97: 123-132.
|
[37] |
McKenzie JA, Mbofung RM, Malu S, et al. The effect of topoisomerase I inhibitors on the efficacy of T-cell-based cancer immunotherapy[J]. J Natl Cancer Inst, 2018, 110(7): 777-786.
|
[38] |
Sistigu A, Yamazaki T, Vacchelli E, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy[J]. Nat Med, 2014, 20(11): 1301-1309.
|
[39] |
Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(22): 2078-2092.
|
[40] |
Reck M, Socinski MA, Cappuzzo F, et al. Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/- bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150)[J]. Ann Oncol, 2017, 28: xi31.
|
[41] |
Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. N Engl J Med, 2018, 379(21): 2040-2051.
|
[42] |
Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study[J]. Ann Oncol, 2019, 30(3): 397-404.
|
[43] |
Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable,locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2020, 21(1): 44-59.
|
[44] |
Arina A, Beckett M, Fernandez C, et al. Tumor-reprogrammed resident T cells resist radiation to control tumors[J]. Nat Commun, 2019, 10(1): 3959.
|
[45] |
Wang XH, Schoenhals JE, Li AL, et al. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy[J]. Cancer Res, 2017, 77(4): 839-850.
|
[46] |
Liu Y, Dong YP, Kong L, et al. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors[J]. J Hematol Oncol, 2018, 11(1): 104.
|
[47] |
Formenti SC, Rudqvist NP, Golden E, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade[J]. Nat Med, 2018, 24(12): 1845-1851.
|
[48] |
Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC[J]. N Engl J Med, 2018, 379(24): 2342-2350.
|
[49] |
Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer[J]. N Engl J Med, 2017, 377(20): 1919-1929.
|
[50] |
Germano G, Lamba S, Rospo G, et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth[J]. Nature, 2017, 552(7683): 116-120.
|
[51] |
Mantso T, Goussetis G, Franco R, et al. Effects of hyperthermia as a mitigation strategy in DNA damage-based cancer therapies[J]. Semin Cancer Biol, 2016, 37/38: 96-105.
|
[52] |
Lerner EC, Edwards RM, Wilkinson DS, et al. Laser ablation: heating up the anti-tumor response in the intracranial compartment[J]. Adv Drug Deliv Rev, 2022, 185: 114311.
|
[53] |
Liu P, Jia SG, Lou Y, et al. Cryo-thermal therapy inducing MI macrophage polarization created CXCL10 and IL-6-rich pro-inflammatory environment for CD4+ T cell-mediated anti-tumor immunity[J]. Int J Hyperth, 2019, 36(1): 407-419.
|
[54] |
Liu K, He K, Xue T, et al. The cryo-thermal therapy-induced IL-6-rich acute pro-inflammatory response promoted DCs phenotypic maturation as the prerequisite to CD4+ T cell differentiation[J]. Int J Hyperth, 2018, 34(3): 261-272.
|
[55] |
Newton JM, Flores-Arredondo JH, Suki S, et al. Non-invasive radiofrequency field treatment of 4T1 breast tumors induces T-cell dependent inflammatory response[J]. Sci Rep, 2018, 8(1): 3474.
|
[56] |
Peng JR, Xiao Y, Li WT, et al. Photosensitizer micelles together with IDO inhibitor enhance cancer photothermal therapy and immunotherapy[J]. Adv Sci (Weinh), 2018, 5(5): 1700891.
|
[57] |
Shi LR, Chen LJ, Wu CP, et al. PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor[J]. Clin Cancer Res, 2016, 22(5): 1173-1184.
|
[58] |
Li XY, Liu JW, Zhang WY, et al. Biogenic hybrid nanosheets activated photothermal therapy and promoted anti-PD-L1 efficacy for synergetic antitumor strategy[J]. ACS Appl Mater Interfaces, 2020, 12(26): 29122-29132.
|
[59] |
Yi M, Jiao DC, Qin S, et al. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment[J]. Mol Cancer, 2019, 18(1): 60.
|
[60] |
B?ckelmann LC, Schumacher U. Targeting tumor interstitial fluid pressure: will it yield novel successful therapies for solid tumors[J]? Expert Opin Ther Targets, 2019, 23(12): 1005-1014.
|
[61] |
Lee WS, Yang H, Chon HJ, et al. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity[J]. Exp Mol Med, 2020, 52(9): 1475-1485.
|
[62] |
Bourhis M, Palle J, Galy-Fauroux I, et al. Direct and indirect modulation of T cells by VEGF-A counteracted by anti-angiogenic treatment[J]. Front Immunol, 2021, 12: 616837.
|
[63] |
Rahma OE, Hodi FS. The intersection between tumor angiogenesis and immune suppression[J]. Clin Cancer Res, 2019, 25(18): 5449-5457.
|
[64] |
Wu FTH, Xu P, Chow A, et al. Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease[J]. Br J Cancer, 2019, 120(2): 196-206.
|
[65] |
Ansari MJ, Bokov D, Markov A, et al. Cancer combination therapies by angiogenesis inhibitors; a comprehensive review[J]. Cell Commun Signal, 2022, 20(1): 49.
|
[66] |
Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426):extended follow-up from a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2020, 21(12): 1563-1573.
|
[67] |
Chesney J, Puzanov I, Collichio F, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma[J]. J Clin Oncol, 2018, 36(17): 1658-1667.
|
[68] |
Sheikh NA, Petrylak D, Kantoff PW, et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer[J]. Cancer Immunol Immunother,2013,62(1): 137-147.
|
[69] |
Fong L, Carroll P, Weinberg V, et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer[J]. J Natl Cancer Inst, 2014, 106(11): dju268.
|
[70] |
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J]. N Engl J Med, 2010, 363(5): 411-422.
|
[71] |
Ku J, Wilenius K, Larsen C, et al. Survival after sipuleucel-T (SIP-T) and low-dose ipilimumab (IPI) in men with metastatic, progressive, castrate-resistant prostate cancer (M-CRPC)[J]. J Clin Oncol, 2018, 36(6 suppl): 368.
|
[72] |
Knudson KM, Hicks KC, Alter S, et al. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy[J]. J Immunotherapy Cancer, 2019, 7(1): 82.
|
[73] |
Adusumilli PS, Zauderer MG, Rivière I, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab[J]. Cancer Discov, 2021, 11(11): 2748-2763.
|
[74] |
Rafiq S, Yeku OO, Jackson HJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo[J]. Nat Biotechnol, 2018, 36(9): 847-856.
|
[75] |
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma[J]. N Engl J Med, 2015, 373(1): 23-34.
|
[76] |
Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma[J]. N Engl J Med, 2015, 372(21): 2006-2017.
|
[77] |
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma[J]. N Engl J Med, 2019, 381(16): 1535-1546.
|
[78] |
Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma[J]. N Engl J Med, 2022, 386(1): 24-34.
|